TICKERNERD
Menu
KNSAKNSAHealthcare · Drug Manufacturers - Specialty & Generic

KNSA Stock Forecast: Kiniksa Pharmaceuticals International Plc Price Predictions for 2026-2027

Last close, 14 Aug 2026
$77
−1.39% on the day

The 8 Wall Street analysts covering Kiniksa Pharmaceuticals International Plc hold a median 12-month price target of $99 — +28.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 98 of 100 as at 15 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$6.0B
Ticker Nerd rank
98 / 100
Median analyst target
$99
Analysts covering
8
Total return, dividends reinvested
1W
+0.9%
1M
+23.8%
YTD
+86.1%
1Y
+130.6%
From 52W high
−5.2%
From 52W low
+132.3%
$33
$81
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KNSA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Kiniksa Pharmaceuticals International Plc on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
98 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
97
Value
96
Momentum
95
Quality
90
Growth
89
Accruals
77
Revisions
71
Issuance
50
Size
22

Volatility (97): The share price has been relatively steady.

Issuance (50): The company has been issuing shares or taking on financing, diluting existing holders.

Size (22): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

KNSA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KNSA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100$120Oct 25Jan 26Apr 26Jul 26KNSAHigh $108Median $99Low $87

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $87Median $99High $108

The green dot is the last close — the median target sits +28.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
30 July 2026Goldman SachsMaintainsBuy$75 → $90
29 July 2026Canaccord GenuityMaintainsBuy$64 → $98
29 July 2026CitigroupMaintainsBuy$60 → $100
29 July 2026JP MorganMaintainsOverweight$72 → $107
29 July 2026WedbushMaintainsOutperform$72 → $99
23 July 2026Goldman SachsMaintainsBuy$60 → $75
13 July 2026Wells FargoMaintainsOverweight—
13 July 2026Wells FargoMaintainsOverweight$57 → $74
29 June 2026WedbushMaintainsOutperform—
29 Apr 2026Canaccord GenuityMaintainsBuy—
29 Apr 2026CitigroupMaintainsBuy—
29 Apr 2026WedbushMaintainsOutperform—
29 Apr 2026Wells FargoMaintainsOverweight—
28 Apr 2026JefferiesMaintainsBuy—
16 Apr 2026WedbushMaintainsOutperform—
25 Feb 2026WedbushMaintainsOutperform—
25 Feb 2026Wells FargoMaintainsOverweight—
19 Feb 2026Canaccord GenuityInitiatesBuy—
13 Jan 2026WedbushMaintainsOutperform—
29 Oct 2025Goldman SachsMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KNSA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

KNSA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−3.5%
Analysts raising
0
Analysts cutting
1
Fundamentals

Kiniksa Pharmaceuticals International Plc (KNSA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
77.5×

Cheaper than 9% of US stocks

Price / sales
7.1×

Cheaper than 19% of US stocks

Price / book
9.1×

Cheaper than 12% of US stocks

EV / EBITDA
53.6×

Cheaper than 5% of US stocks

Growth & margins
Revenue growth (YoY)
55.4%

Higher than 88% of US stocks

Earnings growth (YoY)
42.6%

Higher than 72% of US stocks

Gross margin
54.2%

Higher than 67% of US stocks

Operating margin
11.2%

Higher than 66% of US stocks

Net margin
9.6%

Higher than 69% of US stocks

Returns & dividend
Return on equity
14.0%

Higher than 72% of US stocks

Return on assets
8.0%

Higher than 88% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

KNSA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
KNSAKiniksa Pharmaceuticals International Plc$6.0B
98
AMRXAmneal Pharmaceuticals, Inc.$5.7B
79
LQDALiquidia Corp.$6.4B
78
LNTHLantheus Holdings, Inc.$6.5B
88
HIMSHims & Hers Health, Inc.$6.6B
17
INDVIndivior Pharmaceuticals, Inc.$4.6B
98
ALKSAlkermes Plc$8.1B
60

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Kiniksa Pharmaceuticals International Plc — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KNSA news & analysis

Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3

MarketBeat · 15 Aug 2026positive

Kiniksa Pharmaceuticals said its marketed recurrent pericarditis treatment ARCALYST continues to grow in commercial performance, and the company has started a pivotal Phase 3 study of its follow-on candidate KPL-387.

Why it matters — For KNSA watchers, ARCALYST's sustained growth supports the commercial franchise while the advancement of KPL-387 into Phase 3 signals progress in the pipeline beyond the current product.

Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference

GlobeNewsWire · 7 Aug 2026neutral

Kiniksa Pharmaceuticals announced that its management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 9:00 a.m. Eastern Time.

Why it matters — A KNSA watcher would care because the company is scheduled to speak at an investor conference, offering an opportunity for management to provide commentary to the investment community.

KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook

Zacks Investment Research · 3 Aug 2026positive

Kiniksa raised its 2026 sales guidance for ARCALYST following a surge in second-quarter revenue, and it is advancing KPL-387 into Phase 3 development as a potential next growth driver. The company discussed these developments during its Q2 earnings call.

Why it matters — A KNSA watcher would care because the raised ARCALYST outlook points to stronger expected performance, while KPL-387's move into Phase 3 signals progress on a future pipeline driver.

Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?

Zacks Investment Research · 30 July 2026positive

Zacks Investment Research reported that Kiniksa Pharmaceuticals International (KNSA) shares have begun to gain, supported by solid upward revisions to earnings estimates.

Why it matters — A KNSA watcher would care because rising earnings estimates can signal improving analyst sentiment about the company's near-term prospects.

Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2026 Earnings Call Transcript

Seeking Alpha · 28 July 2026neutral

Kiniksa Pharmaceuticals International, plc published the transcript of its Q2 2026 earnings call on Seeking Alpha, covering the company's second-quarter financial results and business discussion.

Why it matters — A KNSA watcher would care because earnings call transcripts provide direct insight into management's perspective on the company's quarterly performance and strategic outlook.

FAQ

Frequently asked questions about KNSA stock

What is the KNSA stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Kiniksa Pharmaceuticals International Plc have a median 12-month price target of $99, with estimates ranging from $87 to $108. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KNSA stock a buy right now?

Of the 8 analysts covering Kiniksa Pharmaceuticals International Plc, 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kiniksa Pharmaceuticals International Plc 98 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KNSA?

As at 15 Aug 2026, Kiniksa Pharmaceuticals International Plc ranks 98 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (97 of 100).

Will KNSA stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +28.3% from the last close, and Ticker Nerd's factor model ranks Kiniksa Pharmaceuticals International Plc 98 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KNSA stock forecast for 2030?

No analyst covering Kiniksa Pharmaceuticals International Plc publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KNSA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $87 to $108 over the next 12 months.

How has KNSA stock performed over the past year?

Kiniksa Pharmaceuticals International Plc returned +130.6% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Kiniksa Pharmaceuticals International Plc do?

Kiniksa Pharmaceuticals International, plc is a global biopharmaceutical company dedicated to discovering, developing, and commercializing novel therapies for patients with serious unmet medical needs, particularly in cardiovascular and inflammatory diseases. Its lead product, ARCALYST (rilonacept), is an interleukin-1 inhibitor approved as the first and only FDA-approved treatment for recurrent pericarditis, an inflammatory cardiovascular condition causing debilitating chest pain and inflammation.

What is the latest news on KNSA?

The most recent item we track (MarketBeat, 15 Aug 2026): "Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3". Kiniksa Pharmaceuticals said its marketed recurrent pericarditis treatment ARCALYST continues to grow in commercial performance, and the company has started a pivotal Phase 3 study of its follow-on candidate KPL-387.

Company

About Kiniksa Pharmaceuticals International Plc.

Kiniksa Pharmaceuticals International, plc is a global biopharmaceutical company dedicated to discovering, developing, and commercializing novel therapies for patients with serious unmet medical needs, particularly in cardiovascular and inflammatory diseases. Its lead product, ARCALYST (rilonacept), is an interleukin-1 inhibitor approved as the first and only FDA-approved treatment for recurrent pericarditis, an inflammatory cardiovascular condition causing debilitating chest pain and inflammation. The company advances a robust pipeline of clinical-stage assets, including vixarelimab, a monoclonal antibody in Phase 2b trials for prurigo nodularis, a chronic inflammatory skin disease, and KPL-387, advancing toward Phase 2/3 trials in recurrent pericarditis for potential monthly dosing. Kiniksa emphasizes immune modulation therapies with strong biologic rationale, targeting underserved conditions across multiple therapeutic categories. Through strategic partnerships, such as collaborations for commercialization in the Asia Pacific region and licensing agreements for global development, Kiniksa expands access to its innovative treatments worldwide. Founded in 2015, the company is headquartered in Hamilton, Bermuda, and led by a seasoned leadership team focused on patient-centric innovation in biopharmaceuticals.

CEO Mr. Sanjiv K. Patel · 366 employees · United Kingdom · https://www.kiniksa.com